TP53 and cancer: In four rounds of screenings, based on a shift in mortalin staining from perinuclear (typically characteristic of cancer cells) to pan-cytoplasmic (typically characteristic of normal cells) and nuclear translocation of p53 in treated cells, six compounds were selected.